ArticleCancers2023

Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force "Dermatology for Cancer Patients" International Study.

Pietro Sollena et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.